CGBIO

medical devices

About

CGBIO is a South Korean medical device company founded in 2006, specializing in advanced biomaterials and regenerative medicine technologies. The company focuses on orthopedic and dental applications, as well as wound management. CGBIO is recognized for its comprehensive portfolio, which includes allograft and synthetic bone grafts, spinal implants, GMP-grade growth factors, and total wound care solutions. CGBIO operates a state-of-the-art manufacturing facility that adheres to high production standards. The company emphasizes research and development and has achieved FDA IDE approval for its flagship product, NOVOSIS PUTTY, marking a significant step in its U.S. market entry. CGBIO serves a diverse range of customers, including hospitals, clinics, and global healthcare providers, and is committed to enhancing patient quality of life through innovative medical solutions. Its vision is to become a leading global company in regenerative medicine based on biomaterial technology.

Technologies

Google Font API WordPress.org Google Tag Manager Nginx Mobile Friendly

Keywords

medical equipment manufacturing medical device innovation healthcare services regenerative medicine interventional devices 3d printing in healthcare anti-adhesion barriers interventional cardiology devices global healthcare e-commerce wound care products bioceramic bone fillers r&d investment negative pressure wound therapy aesthetic solutions interventional stents orthopedic implants regulatory approval medical equipment and supplies manufacturing dental materials medical device manufacturing b2b bone/spinal products stem cell therapy medical technology stem cell-based regenerative products product innovation medical devices mdr compliance bioceramic hydroxyapatite

Location

Seoul, Seoul, South Korea

Related Companies

Companies in the same industry